article thumbnail

FCF Pharmaceutical Market Study – 2022

Fox Corporate Finance

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Pharmaceutical Market Study – 2022”. Based on available data from European pharmaceutical providers, the FCF Pharmaceutical Market Study is a detailed and comprehensive.

article thumbnail

FCF Pharmaceutical Market Study – 2021 published

Fox Corporate Finance

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Pharmaceutical Market Study – 2021”. Based on available data from European pharmaceutical providers, the FCF Pharmaceutical Market Study is a detailed and comprehensive.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FRP Corporate Finance advises Kelso Pharma on Alturix acquisition

Accountancy Today

The FRP Corporate Finance debt advisory team has supported pan-European specialist pharmaceutical business, Kelso Pharma (Kelso), on its acquisition of Alturix, a UK pharmaceutical company specialising in developing and commercialising originator and niche branded generics.

article thumbnail

NPV Analysis

Corporate Finance

Recently, Voyageur Pharmaceuticals Ltd. It is always interesting to see a real-world application of concepts you have learned in class. rel eased the results of its capital budgeting analysis of a barium sulfate project in British Columbia, Canada.

article thumbnail

CFO Corner With SCHOTT Pharma’s Almuth Steinkühler

Global Finance

Almuth Steinkhler has been CFO of SCHOTT Pharma, which designs drug containment products and drug delivery systems for pharmaceutical and biotech companies, since August 2022. Originally a division of glass manufacturer Schott AG, the company went public on the Frankfurt Stock Exchange in 2023.

CFO 52
article thumbnail

CFO Corner: Anne-Laure Autret-Cornet, OSE Immunotherapeutics

Global Finance

And we have ongoing important collaborations with other companies such as Boehringer Ingelheim and Veloxis Pharmaceuticals. This involves the development of OSE-230, a novel monoclonal antibody, and included an upfront payment of $48 million with potential milestone payments and royalties.

CFO 52
article thumbnail

Adjoint CEO On Why Treasury Management Needs Blockchain

PYMNTS

Yet, corporate finance especially is “operating, more or less, the same [way] it has for 20 years prior. Real-time access to tracking data through distributed ledger technology is critical for time-sensitive materials, such as pharmaceuticals or [foods].